Amino sugar phosphate levels in Giardia change during cyst wall formation.
The parasite Giardia intestinalis exists as a trophozoite (vegetative) that infects the human small intestine, and a cyst (infective) that is shed in host faeces. Cyst viability in the environment depends upon a protective cyst wall, which consists of proteins and a unique beta(1-3) GalNAc homopolymer. UDP-GalNAc, the precursor for this polysaccharide, is synthesized from glucose by an enzyme pathway that involves amino sugar phosphate intermediates. Using a novel method of microanalysis by capillary electrophoresis, the levels of amino sugar phosphate intermediates in trophozoites before encystment, during a period of active encystment and after the peak of encystment were measured. These levels were used to deduce metabolic control of amino sugar phosphates associated with encystment. Levels of amino sugar phosphate intermediates increased during encystment, and then decreased to nearly non-encysting levels. The most pronounced increase was in glucosamine 6-phosphate, which is the first substrate unique in this pathway, and which is the positive effector for the pathway's putative rate-controlling enzyme, UDP-GlcNAc pyrophosphorylase. Moreover, more UDP-GalNAc than UDP-GlcNAc, its direct precursor, was detected at 24 h. It is postulated that the enhanced UDP-GalNAc is a result of enhanced synthesis of UDP-GlcNAc by the pyrophosphorylase, and its preferential conversion to UDP-GalNAc. These results suggest that kinetics of amino sugar phosphate synthesis in encysting Giardia favours the direction that supports cyst wall synthesis. The enzymes involved in synthesis of UDP-GalNAc and its conversion to cyst wall might be potential targets for therapeutic inhibitors of Giardia infection.
Sener
Keriman
K
Department of Biology, Northeastern University, Boston, MA 02115, USA.
Shen
Zuojun
Z
Program in Glycobiology, Shriver Center at University of Massachusetts Medical School, 200 Trapelo Road, Waltham, MA 02452, USA.
Newburg
David S
DS
Program in Glycobiology, Shriver Center at University of Massachusetts Medical School, 200 Trapelo Road, Waltham, MA 02452, USA.
Jarroll
Edward L
EL
Department of Biology, Northeastern University, Boston, MA 02115, USA.
D000116:Acetylgalactosamine / Q000031:analogs & derivatives* / Q000378:metabolism; D000117:Acetylglucosamine / Q000031:analogs & derivatives* / Q000378:metabolism; D000818:Animals; D002473:Cell Wall / Q000378:metabolism*; D019075:Electrophoresis, Capillary; D005688:Galactosamine / Q000031:analogs & derivatives* / Q000378:metabolism; D016829:Giardia lamblia / Q000254:growth & development* / Q000378:metabolism; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000378:metabolism; D019298:Glucose-6-Phosphate / Q000031:analogs & derivatives* / Q000378:metabolism; D009713:Nucleotidyltransferases / Q000378:metabolism; D013379:Substrate Specificity; D015854:Up-Regulation; D014536:Uridine Diphosphate N-Acetylgalactosamine / Q000378:metabolism*; D014537:Uridine Diphosphate N-Acetylglucosamine / Q000378:metabolism*
C115144:N-acetylgalactosamine-1-phosphate; C001293:glucosamine 6-phosphate; D014537:Uridine Diphosphate N-Acetylglucosamine; D019298:Glucose-6-Phosphate; C041629:galactose-2-amino-6-phosphate; C026146:N-acetylglucosamine-1-phosphate; D014536:Uridine Diphosphate N-Acetylgalactosamine; D005688:Galactosamine; D009713:Nucleotidyltransferases; C023226:UDPacetylglucosamine pyrophosphorylase; D000116:Acetylgalactosamine; D005944:Glucosamine; D000117:Acetylglucosamine